Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Collier

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|April 29, 2017
Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritisGeorge W Reed, David H Collier, Andrew S Koenig, et al.
Clinical Therapeutics|July 12, 2014
Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claimsJeffrey R Curtis, Vernon F Schabert, David J Harrison, et al.
Clinical Rheumatology|March 9, 2017
Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registryLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
Journal of the American Academy of Dermatology|January 19, 2016
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, David M Pariser, et al.
The Journal of Rheumatology|October 3, 2017
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease ActivityLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
RMD Open|January 16, 2021
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combinationVibeke Strand, Philip J Mease, Ervant J Maksabedian Hernandez, et al.
RMD Open|March 14, 2018
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)Philip J Mease, Dafna D Gladman, Ahmed S Samad, et al.
Rheumatology Advances in Practice|November 26, 2019
Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort studyGrant W Cannon, Alan R Erickson, Chia-Chen Teng, et al.
Rheumatology International|July 20, 2019
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world settingPhilip J Mease, Neil A Accortt, Sabrina Rebello, et al.
Arthritis Care & Research|December 17, 2020
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in SacroiliitisDax G Rumsey, Aimee Lougee, Roland Matsouaka, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|April 29, 2017
Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritisGeorge W Reed, David H Collier, Andrew S Koenig, et al.
Clinical Therapeutics|July 12, 2014
Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claimsJeffrey R Curtis, Vernon F Schabert, David J Harrison, et al.
Clinical Rheumatology|March 9, 2017
Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registryLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
Journal of the American Academy of Dermatology|January 19, 2016
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, David M Pariser, et al.
The Journal of Rheumatology|October 3, 2017
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease ActivityLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
RMD Open|January 16, 2021
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combinationVibeke Strand, Philip J Mease, Ervant J Maksabedian Hernandez, et al.
RMD Open|March 14, 2018
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)Philip J Mease, Dafna D Gladman, Ahmed S Samad, et al.
Rheumatology Advances in Practice|November 26, 2019
Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort studyGrant W Cannon, Alan R Erickson, Chia-Chen Teng, et al.
Rheumatology International|July 20, 2019
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world settingPhilip J Mease, Neil A Accortt, Sabrina Rebello, et al.
Arthritis Care & Research|December 17, 2020
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in SacroiliitisDax G Rumsey, Aimee Lougee, Roland Matsouaka, et al.
Pageof 5